FDA Approves First Twice-Yearly PrEP for Long-Acting HIV Prevention

[ad_1]

The US Food and Drug Administration (FDA) recently approved lenacapavir, marketed as Yeztugo, as the first twice-yearly preexposure prophylaxis (PrEP) that reduces HIV risk.

[ad_2]

Source link